Clinical trials: Advanced Age
Acute Myelogenous Leukemia, Acute Myeloid Leukemia
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Clolar (clofarabine injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior…
- Trial name
- NCT00373529
- Testing
- clofarabine
- Where
- 20 sites in United States
- Volunteers
- 116 people
- Sponsor
- Genzyme, a Sanofi Company
Pharmacokinetics of ASP1707, Pharmacodynamics of ASP1707
A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects
This study consists of four parts: Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy young male subjects to evaluate the safety, tolerability pharmacokinetics (PK) and effect on…
- Trial name
- NCT02368912
- Testing
- ASP1707 single dose of dose levels 1 -7, ASP1707 single dose fasted, ASP1707 single dose fed
- Where
- France
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Cancer Pain
Unique Treatment of Oncology Pain in Advanced Cancer
This will be a proof-of-concept, single arm study with a maximum of 20 patients to evaluate preliminary analgesic efficacy and safety of Trichomylin® in patients with advanced cancer (male and female) who suffer from moderate to…
- Trial name
- UTOPIA-1 (NCT06533657)
- Testing
- Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
- Where
- 3 sites in Canada
- Volunteers
- 11 people
- Sponsor
- ZYUS Life Sciences Inc.
Dementia, Alzheimer's Disease and Related Dementias
HomeCare Medication Management for People With Dementia
This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias.
- Trial name
- NCT07872072
- Testing
- HomeCare
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- HiDO Technologies
Avian Influenza
Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine
To assess persistence of antibody titers 17-18 months after primary immunization with two 0.5mL intramuscular (IM) doses of H5N1 influenza vaccine containing H5N1 influenza antigen, as measured by Hemagglutination Inhibition…
- Trial name
- NCT00561184
- Testing
- H5N1 influenza vaccine
- Where
- 3 sites in Italy
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Virus Infections
Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Nine different formulations of the RSVPreF3 OA investigational vaccine were tested in the parent study (NCT03814590). Based on safety and immunogenicity data from the parent study, RSVPreF3 OA investigational vaccine will be…
- Trial name
- NCT04657198
- Testing
- RSVPreF3 OA investigational vaccine (GSK3844766A)
- Where
- 10 sites in United States, Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immunosenescence
The Effect of Prebiotic B-GOS on the Immune Function, Metabolism and Gut Microbiota of Elderly People
The purpose of this study is to determine the effects of prebiotic B-GOS on the immune function, metabolism and gut microbiota of elderly people
- Trial name
- PRIMES (NCT01303484)
- Testing
- Bi2muno® GOS, Maltodextrin
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Clasado
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to stable treatment in elderly patients with…
- Trial name
- NCT01084005
- Testing
- linagliptin
- Where
- 34 sites in Australia, Canada and 3 more
- Volunteers
- 241 people
- Sponsor
- Boehringer Ingelheim
Influenza
Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season
This is a yearly licence tolerability and immunogenicity study of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/strain/0.5mL) in adult and elderly subjects to assess…
- Trial name
- NCT01649713
- Testing
- Fluval AB vaccination
- Where
- 3 sites in Hungary
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Seasonal Influenza
Safety and Immunogenicity of One Dose of Inactivated Trivalent Flu Vaccine Administered to Non-elderly Adult and Elderly Subjects
The present study will evaluate the safety and immunogenicity in healthy people (non-elderly adult and elderly subjects) after one intramuscular (IM) dose of trivalent subunit inactivated flu vaccine.
- Trial name
- NCT01151059
- Testing
- Trivalent subunit inactivated flu vaccine, Formulation 2010-2011
- Where
- 5 sites in Italy
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pharmacokinetics, Healthy Subjects
To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females
The study aimed to compare age and gender differences for increasing doses of mirabegron when given to healthy young and elderly males and healthy young and elderly females.
- Trial name
- NCT01478503
- Testing
- mirabegron OCAS
- Where
- 2 sites in Netherlands
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Epilepsy
A Study to Evaluate the Safety and Tolerability and Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures
A two arm, randomized, double-blind study comparing zonisamide with placebo. The zonisamide arm will consist of 100 subjects and the placebo arm of 50 subjects.
- Trial name
- NCT01546688
- Testing
- Zonisamide at targeted daily doses of 100-500 mg/day
- Where
- 36 sites in Germany, Hungary and 5 more
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Venous Leg Ulcer
Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population
This study is designed to assess the clinical effectiveness of Membrane Wrap, a human amniotic membrane for the management of difficult to heal partial- or full-thickness venous leg ulcers (VLUs)
- Trial name
- NCT06544564
- Testing
- Membrane Wrap™, Standard of Care
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- BioLab Holdings
Healthy, Pharmacokinetics of ASP2408
A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single subcutaneous dose of ASP2408 in non-elderly healthy adult male subjects. The pharmacodynamics of ASP2408 is also being evaluated.
- Trial name
- NCT02140125
- Testing
- ASP2408
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Frailty, Muscle Loss
A Randomized-Control Study of Gym Tonic's Community Based Strength Training Intervention.
Launched in April 2015 , Gym Tonic is the first of its kind cross-border exercise-as-medicine partnership between research institutions, business enterprises and service providers from Singapore and Finland.
- Conditions
- Frailty, Muscle Loss, Sarcopenia
- Trial name
- NCT04661618
- Testing
- Gym Tonic programme and Gym equipment
- Where
- Singapore
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- PulseSync Pte Ltd
Healthy Subjects
Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.
This study will test the safety, tolerability and blood concentrations of single and multiple oral doses of PF-06751979 in health subjects and healthy elderly subjects.
- Trial name
- NCT02793232
- Testing
- PF-06751979 single dose, PF-06751979 multiple ascending dose, PF-06751979 multiple dose
- Where
- Belgium
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK, or amount of drug over time in the body) and pharmacodynamics (PD, or effects on the body) of ACT-541468 following multiple ascending doses…
- Trial name
- NCT02571855
- Testing
- ACT-541468 (hydrochloride salt), ACT-541468 (free base)
- Where
- Netherlands
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy Volunteers, Norovirus
Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults
The purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 NoV vaccine administration.
- Trial name
- NCT03039790
- Testing
- NoV Vaccine
- Where
- 11 sites in United States, Belgium
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population
To assess the safety and tolerability of ascending, multiple, oral doses of GSI-953 in healthy elderly subjects.
- Trial name
- NCT00547560
- Testing
- GSI-953
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Age-Related Maculopathy, Age-Related Maculopathies
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration
- Trial name
- NCT01003691
- Testing
- RN6G
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.